Eluryng Ring
Product Images NDC 65162-469

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Eluryng (NDC 65162-469). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Eluryng 1)

A horizontal bar chart showing the number of women with blood clots per 10,000 woman-years in different categories: Non-CHC Users Non-Pregnant (range 1 to 5), CHC Users (range 3 to 12), Pregnant women (range 5 to 20), and Postpartum women at 12 weeks only (range 40 to 65). The chart compares blood clot risk across these groups.*

FDA Label Image

Figure J (Eluryng 10)

Instructional illustration showing the proper hand insertion of a vaginal ring, depicting the ring being positioned inside the vaginal canal. The three-panel diagram demonstrates step-by-step placement from external to internal views to guide users on how to insert the ring correctly.*

FDA Label Image

Pouch Label (Eluryng 11)

An instructional anatomical illustration showing the vaginal insertion of EluRyng, a vaginal ring contraceptive containing etonogestrel and ethinyl estradiol. The diagram depicts a hand inserting the ring into the vaginal canal, demonstrating correct placement within the female reproductive anatomy.*

FDA Label Image

Carton Label (Eluryng 12)

EluRyng ring packaging label by Amneal Pharmaceuticals LLC. The front displays the product name EluRyng with active ingredients etonogestrel and ethinyl estradiol, delivering 0.120 mg and 0.015 mg per day, respectively. The dosage form is a vaginal ring. The back includes usage information and the NDC 65162-469.*

FDA Label Image

Peel Off (Eluryng 13)

Packaging label for EluRyng vaginal ring by Amneal Pharmaceuticals LLC. The ring contains etonogestrel and ethinyl estradiol, delivering 0.120 mg and 0.015 mg per day respectively. The label indicates it requires refrigeration for the dispenser and contains three rings per package. It includes storage and dispensing instructions with a barcode and contact information.*

FDA Label Image

Pharma Label (Eluryng 14)

EluRyng packaging label showing adhesive reminder stickers for use on a calendar. The stickers have icons with "In" and "Out" indications to assist users in tracking insertion and removal dates of the etonogestrel/ethinyl estradiol vaginal ring. The label includes spaces for recording dates and a barcode on the left. The labeler is Amneal Pharmaceuticals LLC.*

FDA Label Image

Eluryng 15

This image shows dispensing instructions for the etonogestrel/ethinyl estradiol vaginal ring. It directs the dispenser to place an expiration date label on the pouch and outer carton, with expiration not exceeding 4 months from dispensing or preprinted date. The label must cover preexisting expiration dates. A table is included to document labeling and resealing by the pharmacy.*

FDA Label Image

Formula (Eluryng 2)

A forest plot chart titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives' showing effect estimates from various studies comparing breast cancer risk between Ever COC users vs. Never users and Current COC users vs. Never users. The horizontal axis represents the effect estimate ranging approximately from -1.50 to 2.00. Each study is listed on the left with corresponding plotted points and confidence intervals, along with their odds ratio (OR), relative risk (RR), or hazard ratio (HR) on the right side.*

FDA Label Image

Figure 2 (Eluryng 3)

Chemical structures of the active ingredients Etonogestrel and Ethinyl Estradiol for the drug EluRyng. Each structure includes molecular formulas and key functional groups depicted in a standard skeletal formula format.*

FDA Label Image

Pic 1 (Eluryng 4)

A line graph depicting plasma concentrations of Etonogestrel and Ethinyl Estradiol (EE) over 21 days after EluRyng vaginal ring insertion. The y-axis on the left shows Etonogestrel levels in pg/mL, reaching around 1500 pg/mL, while the y-axis on the right shows EE levels, remaining near 50 pg/mL. The x-axis represents days after insertion, from 0 to 21.*

FDA Label Image

Pic 2 (Eluryng 5)

An illustration showing a vertical scale of pregnancy rates per 100 women in one year, ranging from fewer than 1 pregnancy to 85 or more pregnancies. Various birth control methods are categorized along this scale, including implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, no sex during fertile days, spermicide, withdrawal, and no birth control.*

FDA Label Image

Figure Abc (Eluryng 6)

Bar chart showing the estimated ranges of number of women with a blood clot out of 10,000 woman-years across four groups: Non-CHC user non-pregnant (1 to 5), CHC user (3 to 12), Pregnancy (5 to 20), and Postpartum (12 weeks only) with the highest range (40 to 65).*

FDA Label Image

Figure De (Eluryng 7)

Illustrations demonstrating three different positions for inserting the EluRyng vaginal ring. The images show a person lying down with knees bent, squatting, and standing with one leg raised on a step, demonstrating recommended postures for vaginal ring insertion.*

FDA Label Image

Figure F (Eluryng 8)

Illustration showing a hand holding the EluRyng vaginal ring by pinching it between the thumb and fingers. The second image shows the ring being compressed or folded by the fingers, likely demonstrating how to insert or handle the ring.*

FDA Label Image

Figure Ghi (Eluryng 9)

An anatomical diagram showing the placement of the Etonogestrel and Ethinyl Estradiol vaginal ring inside the female reproductive tract. The uterus and vagina are labeled to indicate where the vaginal ring is positioned for use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.